Medpace (NASDAQ:MEDP) Director Brian Carley Sells 5,000 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Brian Carley sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the transaction, the director directly owned 27,825 shares in the company, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Medpace Trading Up 1.3%

NASDAQ:MEDP opened at $620.75 on Friday. The company has a 50-day moving average price of $550.16 and a 200-day moving average price of $492.71. The stock has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a P/E/G ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the company earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MEDP. Johnson Financial Group Inc. bought a new position in Medpace during the 2nd quarter valued at about $27,000. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Elyxium Wealth LLC purchased a new stake in Medpace in the 4th quarter worth about $30,000. Jones Financial Companies Lllp bought a new stake in Medpace in the second quarter worth about $30,000. Finally, Allied Private Wealth LLC bought a new stake in Medpace in the second quarter worth about $31,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Robert W. Baird raised their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.